Unlocking the Potential of IGKV1D-17 as a Drug Target and Biomarker

Target Name: IGKV1D-17

NCBI ID: G28900

Other Name(s): Immunoglobulin kappa variable 1D-17 | L14 | IGKV1D17 | immunoglobulin kappa variable 1D-17

Unlocking the Potential of IGKV1D-17 as a Drug Target and Biomarker

Introduction

Immunoglobulin kappa variable 1D-17 (IGKV1D-17) is a protein that plays a crucial role in the immune system's response to various infections and diseases. Its high expression levels and unique structure have made it an attractive target for drug development. In this article , we will explore the potential of IGKV1D-17 as a drug target and biomarker.

Drug Target Potential

IGKV1D-17 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes that are crucial for the immune response. IGKV1D-17 has been shown to play a role in the regulation of T cell proliferation, differentiation , and survival. It has also been shown to be involved in the regulation of inflammation and immune cell function. These properties make IGKV1D-17 an attractive target for drug development due to its potential to modulate the immune response and improve overall health.

Biomarker Potential

IGKV1D-17 has also been identified as a potential biomarker for various diseases. Its high expression levels and unique structure make it an attractive candidate for use as a diagnostic or predictive marker for diseases such as cancer, autoimmune disorders, and infectious diseases. IGKV1D- 17 has also been shown to have potential as a biomarker for monitoring the effectiveness of cancer treatments and assessing the impact of vaccines on immune response.

Current Research

While IGKV1D-17 is still in the early stages of research, what is known is that it has a unique structure that gives it unique properties. Studies have shown that IGKV1D-17 has a distinct N-terminus, a unique central region, and a unique C-terminus. These features make IGKV1D-17 different from other proteins, and they may be the key to its unique functions in the immune system.

Conclusion

In conclusion, IGKV1D-17 is an attractive target for drug development due to its unique structure and its involvement in various cellular processes that are crucial for the immune response. As a potential biomarker, IGKV1D-17 may be useful in monitoring the effectiveness of cancer treatments and assessing the impact of vaccines on immune response. Further research is needed to fully understand the unique properties of IGKV1D-17 and its potential as a drug target and biomarker.

Protein Name: Immunoglobulin Kappa Variable 1D-17

Functions: V region of the variable domain of immunoglobulin light chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:20176268, PubMed:22158414). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

More Common Targets